ATRX — Adhera Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $0.06m
- $8.45m
C2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.076 | 0.252 | 0 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | -0.208 | -0.157 | 0 | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 16.7 | 11.6 | 2.04 | 0.815 | 1.28 |
Operating Profit | -16.6 | -11.3 | -2.04 | -0.815 | -1.28 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -16.8 | -12 | -3.77 | -6.35 | -2.11 |
Provision for Income Taxes | |||||
Net Income After Taxes | -16.8 | -12 | -3.77 | -6.35 | -2.11 |
Net Income Before Extraordinary Items | |||||
Net Income | -16.8 | -12 | -3.77 | -6.35 | -2.11 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -17.8 | -13.5 | -5.31 | -8.4 | -2.73 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -21.8 | -22.8 | -9.76 | -12.7 | -1.33 |